166 related articles for article (PubMed ID: 16631461)
1. Changing perspectives of the role of chemotherapy in advanced prostate cancer.
Burgess EF; Roth BJ
Urol Clin North Am; 2006 May; 33(2):227-36, vii. PubMed ID: 16631461
[TBL] [Abstract][Full Text] [Related]
2. Current chemotherapeutic approaches for androgen-independent prostate cancer.
Rumohr JA; Chang SS
Curr Opin Investig Drugs; 2006 Jun; 7(6):529-33. PubMed ID: 16784023
[TBL] [Abstract][Full Text] [Related]
3. Optimal timing of chemotherapy in androgen independent prostate cancer.
Schnadig ID; Beer TM
Urol Oncol; 2009; 27(1):97-100. PubMed ID: 19111808
[TBL] [Abstract][Full Text] [Related]
4. The evolving role of chemotherapy in androgen-independent (hormone-refractory) prostate cancer.
Berry WR
Urology; 2005 Jun; 65(6 Suppl):2-7. PubMed ID: 15939076
[TBL] [Abstract][Full Text] [Related]
5. Future directions in the treatment of androgen-independent prostate cancer.
Petrylak DP
Urology; 2005 Jun; 65(6 Suppl):8-12. PubMed ID: 15939077
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic options in androgen-independent prostate cancer: building on docetaxel.
Petrylak D
BJU Int; 2005 Dec; 96 Suppl 2():41-6. PubMed ID: 16359438
[TBL] [Abstract][Full Text] [Related]
7. The current role of chemotherapy in metastatic hormone-refractory prostate cancer.
Petrylak DP
Urology; 2005 May; 65(5 Suppl):3-7; discussion 7-8. PubMed ID: 15885271
[TBL] [Abstract][Full Text] [Related]
8. Current indications for chemotherapy in prostate cancer patients.
Calabrò F; Sternberg CN
Eur Urol; 2007 Jan; 51(1):17-26. PubMed ID: 17007996
[TBL] [Abstract][Full Text] [Related]
9. Actual chemotherapeutical possibilities in hormone-refractory prostate cancer (HRPC) patients.
Prezioso D; Galasso R; Di Martino M; Iapicca G; Annunziata E; Iacono F
Anticancer Res; 2007; 27(2):1095-104. PubMed ID: 17465249
[TBL] [Abstract][Full Text] [Related]
10. Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy.
Berry W; Eisenberger M
Oncologist; 2005; 10 Suppl 3():30-9. PubMed ID: 16368869
[TBL] [Abstract][Full Text] [Related]
11. Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: scientific basis and design of Southwest Oncology Group Study 9916.
Hussain M; Petrylak D; Fisher E; Tangen C; Crawford D
Semin Oncol; 1999 Oct; 26(5 Suppl 17):55-60. PubMed ID: 10604271
[TBL] [Abstract][Full Text] [Related]
12. Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts.
Oudard S; Legrier ME; Boyé K; Bras-Gonçalves R; De Pinieux G; De Cremoux P; Poupon MF
J Urol; 2003 May; 169(5):1729-34. PubMed ID: 12686819
[TBL] [Abstract][Full Text] [Related]
13. An interdisciplinary approach to treating prostate cancer.
Kibel AS
Urology; 2005 Jun; 65(6 Suppl):13-8. PubMed ID: 15939078
[TBL] [Abstract][Full Text] [Related]
14. Doxetaxel: new indication. Prostate cancer: a few more weeks.
Prescrire Int; 2006 Feb; 15(81):6-7. PubMed ID: 16548096
[TBL] [Abstract][Full Text] [Related]
15. Recent docetaxel studies establish a new standard of care in hormone refractory prostate cancer.
Van Poppel H
Can J Urol; 2005 Feb; 12 Suppl 1():81-5. PubMed ID: 15780173
[TBL] [Abstract][Full Text] [Related]
16. Current status of cytotoxic chemotherapy in patients with metastatic prostate cancer.
Dreicer R
Urol Oncol; 2008; 26(4):426-9. PubMed ID: 18593622
[TBL] [Abstract][Full Text] [Related]
17. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
Efstathiou E; Bozas G; Kostakopoulos A; Kastritis E; Deliveliotis C; Antoniou N; Skarlos D; Papadimitriou C; Dimopoulos MA; Bamias A
Urology; 2005 Jan; 65(1):126-30. PubMed ID: 15667877
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy in advanced prostate cancer.
Beedassy A; Cardi G
Semin Oncol; 1999 Aug; 26(4):428-38. PubMed ID: 10482185
[TBL] [Abstract][Full Text] [Related]
19. What next after hormonotherapy in cancer prostate?
Parvez T; Al-sisi H; Ibraheim I
J Coll Physicians Surg Pak; 2003 Oct; 13(10):606-10. PubMed ID: 14588180
[TBL] [Abstract][Full Text] [Related]
20. Update in the management of patients with hormone-refractory prostate cancer.
Moore CN; George DJ
Curr Opin Urol; 2005 May; 15(3):157-62. PubMed ID: 15815191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
